Scribe Therapeutics Advances CRISPR Cholesterol Therapy STX-1150 to Phase I Trials in Mid-2026
核心洞察
Scribe Therapeutics (搜索) plans to initiate first-in-human Phase I trials for STX-1150 in mid-2026, targeting hypercholesterolemia (搜索) through PCSK9 epigenetic silencing.
Preclinical studies demonstrate over 50% LDL-C (搜索) reduction in non-human primates sustained for approximately 18 months after a single administration.
The therapy uses proprietary ELXR technology to durably silence genes without permanent DNA modification, potentially addressing adherence challenges of current lipid-lowering treatments.
Scribe Therapeutics (搜索) announced plans to advance its lead cardiometabolic therapy STX-1150 into Phase I human trials by mid-2026, marking a significant milestone in the development of CRISPR-based treatments for cardiovascular disease (搜索). The novel therapy targets hypercholesterolemia (搜索) through epigenetic silencing of the PCSK9 gene, offering a potentially transformative approach to cholesterol management that could replace daily medications with a single treatment.
Breakthrough Preclinical Results Drive Clinical Advancement
STX-1150 demonstrated remarkable durability in preclinical studies, achieving greater than 50% reduction in low-density lipoprotein cholesterol (LDL-C (搜索)) in non-human primates that was sustained for approximately 18 months following a single administration at doses below 1.0 mg/kg. The therapy was generally well tolerated with no significant liver enzyme elevations compared to controls, according to company data.
"Entering the clinic with STX-1150 represents a defining moment for Scribe and the wider genetic medicine field," said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics (搜索). "We designed STX-1150 to overcome many of the limitations of today's lipid-lowering therapies through powerful epigenetic silencing, and to meaningfully change how cardiovascular risk is managed for millions of patients."
Novel ELXR Technology Enables Reversible Gene Silencing
STX-1150 leverages Scribe's proprietary Epigenetic Long-Term X-Repressor (ELXR) technology, which differs fundamentally from traditional CRISPR gene editing approaches. Rather than permanently altering DNA sequences, ELXR uses a nuclease-inactivated, CasX-derived CRISPR protein fused to epigenetic effector domains to install histone modifications and DNA methylation marks at the PCSK9 locus in liver cells.
The technology incorporates an allosteric regulatory domain that adds built-in specificity controls designed to reduce off-target effects while maintaining or enhancing on-target activity. In studies detailed in a new preprint, allosteric ELXR reduced off-target transcriptome-wide perturbations while maintaining or enhancing on-target repression across genomic loci with an average of at least 4-fold increased activity compared to existing epigenetic editors.
Addressing Critical Unmet Medical Need
Cardiovascular disease (搜索) represents the leading cause of death worldwide, impacting over 120 million individuals in the United States alone. Every 40 seconds, someone in the United States suffers a heart attack, with heart disease costing the nation more than $400 billion annually, according to company data.
Current lipid-lowering therapies face significant limitations including lack of durability, diminishing adherence-adjusted efficacy, and onerous treatment burdens with well-documented side effects. These factors lead to poor uptake, low adherence, and limited real-world effectiveness, with treatment often initiated only after decades of arterial damage or acute cardiovascular events.
PCSK9 as Validated Therapeutic Target
STX-1150 targets PCSK9, a genetically and clinically validated target for LDL-C (搜索) reduction. Inhibition of PCSK9 represents one of the most effective known mechanisms to reduce LDL-C, complementing or outperforming existing therapies such as statins (搜索), bempedoic acid, ezetimibe, and emerging CETP inhibitors.
Individuals born with loss-of-function variants in the PCSK9 gene experience meaningfully lower baseline LDL-C (搜索) levels and up to 88% lower risk for coronary heart disease (搜索) without distinguishable adverse effects from lifetime lower LDL-C levels, providing strong genetic validation for the therapeutic approach.
Clinical Development and Market Implications
The planned Phase I study will evaluate safety and tolerability of STX-1150 in individuals with hypercholesterolemia (搜索) at elevated cardiovascular risk. If successful, the therapy could represent the first approved genetic-silencing method for cardiovascular disease (搜索), potentially transforming treatment from chronic medication management to a one-time intervention.
The development comes as CRISPR technology rapidly advances, with the FDA approving the first CRISPR/Cas9 therapy for sickle cell disease in 2024. However, accessibility remains a concern, as current CRISPR therapies like Casgevy cost approximately $2.2 million per patient.
Scribe Therapeutics (搜索), co-founded by Nobel Prize winner Jennifer Doudna, has established strategic collaborations with pharmaceutical giants Sanofi and Eli Lilly to broaden the impact of its engineered CRISPR technologies. The company's approach focuses on developing scalable, transformative genetic medicines aimed at democratizing access to the protective effects of beneficial human genetics for the estimated 70 million Americans with chronically high cholesterol.